Zevra Therapeutics Announces Departure of Chief Development Officer and Chief Scientific Officer

ZEVRA THERAPEUTICS, INC.

Christal Mickle, Chief Development Officer and Co-Founder, notified of departure effective Dec. 6, 2024.
Sven Guenther, Ph.D., Chief Scientific Officer, departing Zevra effective Dec. 23, 2024.
Development and scientific functions consolidated under Chief Medical Officer Adrian Quartel, M.D.
In-house drug discovery discontinued; laboratory facilities in Iowa and Virginia to close.
Changes include elimination of positions in CMC and Clinical Development as part of strategic plan.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.